Retatrutide: The Triple-Agonist That Changed Weight Loss Forever

What Is Retatrutide?

Retatrutide (LY3437943) is a first-in-class triple-agonist peptide developed by Eli Lilly that simultaneously targets three metabolic receptors: GLP-1, GIP, and glucagon. No other compound in clinical development activates all three pathways at once, making Retatrutide the most powerful metabolic optimization agent ever studied.

In Phase 2 clinical trials published in the New England Journal of Medicine and JAMA in 2023, Retatrutide achieved up to 24.2% body weight reduction at the 12mg dose over 48 weeks. To put that in perspective, semaglutide (the active ingredient in Ozempic and Wegovy) achieves approximately 15% weight loss, and tirzepatide (Mounjaro) achieves approximately 20%. Retatrutide surpasses both.

The compound is currently in Phase 3 clinical trials under Eli Lilly's TRIUMPH program, with studies examining its efficacy across obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD, formerly NAFLD/NASH).

The Triple-Agonist Mechanism

Understanding why Retatrutide outperforms every other weight loss compound requires understanding what each receptor does and why activating all three simultaneously creates a synergistic effect no single or dual agonist can replicate.

GLP-1 receptor activation suppresses appetite through central nervous system signaling, slows gastric emptying to increase satiety, and stimulates glucose-dependent insulin secretion. This is the same mechanism semaglutide uses. On its own, it produces meaningful weight loss — but it represents only one-third of Retatrutide's mechanism.

GIP receptor activation enhances insulin sensitivity in adipose tissue, improves lipid metabolism, and may contribute to reduced fat storage. Tirzepatide was the first approved drug to combine GLP-1 and GIP agonism, which is why it outperforms semaglutide. Retatrutide includes this mechanism plus one more.

Glucagon receptor activation is the differentiator. Glucagon increases hepatic energy expenditure, promotes the breakdown of stored fat through lipolysis, and critically reduces liver fat accumulation. This is the mechanism no other obesity drug on the market targets. The glucagon component means Retatrutide doesn't just reduce caloric intake — it actively increases the rate at which your body burns stored fat and clears lipids from the liver.

The combination of appetite suppression (GLP-1), improved fat metabolism (GIP), and increased energy expenditure plus liver fat clearance (glucagon) creates a metabolic transformation that goes far beyond simple weight loss.

Phase 2 Trial Results

The Phase 2 trial data for Retatrutide, published in JAMA in June 2023, enrolled 338 adults with obesity and evaluated three dose levels over 48 weeks.

At the 12mg dose, participants lost an average of 24.2% of their body weight — the highest efficacy of any obesity pharmacotherapy ever tested in a clinical trial. At the 8mg dose, average weight loss was 22.1%. Even the lowest 4mg dose produced 17.9% weight loss, which exceeds semaglutide's typical results.

Beyond weight loss, the trial showed significant improvements in metabolic markers including HbA1c, fasting glucose, fasting insulin, triglycerides, and liver fat content. The liver fat findings were particularly notable, with some participants showing near-complete resolution of hepatic steatosis — a finding driven by the glucagon receptor component.

Adverse events were consistent with the GLP-1 drug class, primarily gastrointestinal in nature: nausea, diarrhea, vomiting, and constipation. These were most common during dose titration and generally decreased with continued treatment. Gradual dose escalation significantly reduced the incidence and severity of GI side effects.

Retatrutide vs Semaglutide vs Tirzepatide

The competitive landscape for metabolic peptides is defined by receptor targets and resulting efficacy.

Semaglutide targets one receptor (GLP-1) and achieves approximately 15% weight loss. It is FDA-approved and widely available under brand names Ozempic (diabetes) and Wegovy (obesity).

Tirzepatide targets two receptors (GLP-1 and GIP) and achieves approximately 20-22% weight loss. It is FDA-approved under brand names Mounjaro (diabetes) and Zepbound (obesity).

Retatrutide targets three receptors (GLP-1, GIP, and glucagon) and achieves up to 24.2% weight loss. It is currently in Phase 3 trials and available through compounding with a physician's prescription.

The glucagon receptor activation gives Retatrutide a unique advantage in two areas no other compound addresses: increased energy expenditure (you burn more calories at rest) and hepatic fat clearance (liver fat is actively reduced). For individuals with metabolic syndrome, MASLD, or significant visceral fat, this triple mechanism offers a fundamentally different approach than appetite suppression alone.

Dosing and Titration

Retatrutide is administered as a once-weekly subcutaneous injection. The critical principle in Retatrutide dosing is gradual titration — starting at a low dose and increasing slowly to minimize gastrointestinal side effects.

A typical physician-supervised titration schedule starts at 1mg weekly for the first 4 weeks, increases to 4mg weekly for weeks 5-8, then moves to 8mg weekly for weeks 9-12, with a potential increase to 12mg based on response and tolerability.

Dose titration is not optional. Jumping to higher doses without gradual escalation significantly increases the risk of nausea, vomiting, and other GI side effects. This is precisely why physician supervision matters — your doctor monitors your tolerance and adjusts the titration timeline to your individual response.

Injection timing is flexible — any time of day, any day of the week, as long as you maintain consistency. Subcutaneous injection in the abdomen, thigh, or upper arm are all acceptable sites, with rotation recommended to prevent injection site reactions.

Managing Side Effects

The most common side effects mirror those of other GLP-1 class medications and are primarily gastrointestinal: nausea (most common, especially during titration), decreased appetite (which is partly the mechanism of action), diarrhea or constipation, and occasional vomiting during dose increases.

Management strategies that physicians commonly recommend include eating smaller meals more frequently, avoiding high-fat meals during titration weeks, staying well-hydrated, taking anti-nausea medication if prescribed, and slowing the titration schedule if symptoms are significant.

Most patients report that GI side effects are strongest during the first 2-3 weeks of each dose increase and diminish substantially with continued use at the same dose.

Accessing Retatrutide

Retatrutide is available through compounding pharmacies with a physician's prescription. At Longevity AI, Retatrutide is part of our Metabolic Optimization protocol, which pairs it with MOTS-C for metabolic amplification and NMN for cellular energy support during body recomposition.

Our Health Quiz identifies whether Retatrutide is appropriate for your goals and health profile. If metabolic optimization is indicated, your physician consultation includes a thorough review of your metabolic health, medication interactions, and a customized titration plan.

The Longevity AI Dose Calculator supports Retatrutide with accurate reconstitution math for your specific vial size and target dose. The Progress Tracker lets you log your weekly doses, track weight and wellness trends, and share your data with your physician at each check-in.